SEC Filing Summary: Heatwurx, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Heatwurx, Inc., a Delaware corporation, on September 4, 2015. The report discloses corporate governance changes effective as of August 31, 2015. Note: The request metadata references "Processa Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as "Heatwurx, Inc."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Director Resignation: David Dworsky resigned from his position as a director on August 31, 2015.
- Director Appointment: John McGrain was appointed as a director on August 31, 2015, replacing Mr. Dworsky.
- Committee Assignments: Mr. McGrain has not been appointed to any committees, and there are currently no plans for such appointments.
Management Commentary and Risks
Management confirmed that there were no disagreements between Mr. Dworsky and the Company regarding operations, policies, or practices in connection with his resignation. No other risks, contingencies, guidance, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following the appointment of John McGrain.
- Confirm whether the resignation of David Dworsky impacts any ongoing strategic initiatives or committee functions.
- Check subsequent filings for any committee assignments for the new director.